Stock Events

Stock Events

Spruce Biosciences 

$8.35
52
-$0.15-1.76% Wednesday 20:00

Statistics

Day High
9.29
Day Low
8.06
52W High
45.6
52W Low
4.28
Volume
2,706
Avg. Volume
3,605
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

12MarExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
-24
-17.17
-10.33
-3.5
Expected EPS
-9.4725
Actual EPS
N/A

Financials

-1,079.94%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
4.91MRevenue
-53.04MNet Income

Analyst Ratings

138.83Average Price Target
The highest estimate is 160.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
83%
Hold
17%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Crinetics Pharmaceuticals
CRNX
Mkt Cap9B
Crinetics Pharmaceuticals focuses on endocrine diseases and disorders, directly competing with Spruce Biosciences' focus on endocrinology and rare diseases.
Neurocrine Biosciences
NBIX
Mkt Cap15.66B
Neurocrine Biosciences is involved in neuroendocrine and endocrine diseases, overlapping with Spruce Biosciences' therapeutic areas.
Madrigal Pharmaceuticals
MDGL
Mkt Cap12.33B
Madrigal Pharmaceuticals works on metabolic disorders, a field that intersects with Spruce Biosciences' focus on hormonal disorders.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals engages in the treatment of cystic fibrosis and other serious diseases, competing for similar resources and investment in the biotech space.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on human therapeutics, including treatments for endocrine-based disorders, competing in the broader biopharmaceuticals market.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, known for its innovative treatments, competes in the same biopharma space, targeting similar diseases as Spruce Biosciences.
Ligand Pharmaceuticals
LGND
Mkt Cap5.59B
Ligand Pharmaceuticals offers a business model that includes developing drugs for rare diseases, directly competing with Spruce Biosciences' niche focus.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals focuses on RNAi therapeutics for rare genetic diseases, competing in the rare disease market space.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical specializes in enzyme replacement therapies for rare genetic disorders, directly competing in the rare diseases sector.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics, competing in the genetic medicine and rare diseases market.

About

Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
Show more...
CEO
Javier Szwarcberg
Employees
8
Country
United States

Listings

XNAS
US
SPRB
BOATS
BOATS
SPRB.BOATS

0 Comments

Share your thoughts

FAQ

What is Spruce Biosciences stock price today?▼
The current price of SPRBD is $8.35 USD — it has decreased by -1.76% in the past 24 hours. Watch Spruce Biosciences stock price performance more closely on the chart.
What is Spruce Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTCM exchange Spruce Biosciences stocks are traded under the ticker SPRBD.
Is Spruce Biosciences stock price growing?▼
SPRBD stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Spruce Biosciences has showed a -7.22% decrease.
What is Spruce Biosciences revenue for the last year?▼
Spruce Biosciences revenue for the last year amounts to 4.91M USD.
What is Spruce Biosciences net income for the last year?▼
SPRBD net income for the last year is -53.04M USD.
How many employees does Spruce Biosciences have?▼
As of September 05, 2026, the company has 8 employees.
In which sector is Spruce Biosciences located?▼
Spruce Biosciences operates in the Health & Wellness sector.
When did Spruce Biosciences complete a stock split?▼
The last stock split for Spruce Biosciences was on August 07, 2025 with a ratio of 1:75.
Where is Spruce Biosciences headquartered?▼
Spruce Biosciences is headquartered in SOUTH SAN FRANCISCO, United States.